CTXR logo

CTXR
Citius Pharmaceuticals Inc

21,635
Mkt Cap
$23.09M
Volume
323,697.00
52W High
$12.84
52W Low
$0.65
PE Ratio
-0.25
CTXR Fundamentals
Price
$1.25
Prev Close
$1.24
Open
$1.20
50D MA
$1.34
Beta
1.08
Avg. Volume
1.42M
EPS (Annual)
-$5.97
P/B
0.28
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Announces the Closing of Registered Direct...
PR Newswire·19d ago
News Placeholder
More News
News Placeholder
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million...
PR Newswire·19d ago
News Placeholder
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences PR...
PR Newswire·23d ago
News Placeholder
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to...
PR Newswire·24d ago
News Placeholder
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and...
PR Newswire·9mo ago
News Placeholder
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services Citius Pharmaceuticals and Citius Oncology Announce Unique...
PR Newswire·9mo ago
News Placeholder
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced...
PR Newswire·10mo ago
News Placeholder
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch...
PR Newswire·10mo ago
News Placeholder
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives...
PR Newswire·10mo ago
News Placeholder
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital...
Yahoo! Finance: News·10mo ago

Latest CTXR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.